MedX Health Announces Addition of Two New Screening Services Locations in Ottawa
27 Enero 2022 - 7:30AM
Business Wire
MedX Health with ProMed Pharmacy and Dura
Wellness Clinic launches Dermsecure® Screening
Teledermatology company MedX Health Corp. ("MedX" or the
"Company") (TSXV: MDX) is pleased to announce the launch of
MedX Screening Services to be offered at two locations in Ottawa,
Canada – ProMed Pharmacy, an independent, pharmacist owned pharmacy
enterprise, and Dura Wellness Clinic a retail, clinical focused
esthetic services group. Both locations will now offer MedX
scanning services and accept walk-in patients.
"This represents the next step in our business plan for North
America," stated MedX VP of North American Sales, Paul Ziemer.
"ProMed Pharmacy, under the Leadership of Lubna Fawaz, is a perfect
model of modern health care delivery as it integrates many services
and, most importantly, telehealth services on demand for their
patients. Patients can now enter the pharmacy and have a
telemedicine consult with a General Practitioner and receive an
immediate referral to the Dermsecure Screening Service on site.
Incorporating a telemedicine consult with a General Practitioner is
a vital step to make DermSecure screening services easily
accessible to the public by facilitating both the referral and the
screening at the same location."
ProMed Pharmacy now offering MedX Health Dermatological
Screening Services:
- 2706 Alta Vista Dr. Ottawa, Ontario (Tel: 613-680-4343)
- 2 Pharmacists on staff
- Pharmacist Owner - Lubna Fawaz
Dura Wellness Clinic is now offering MedX Health
Dermatological Screening Services:
- 2283 St. Laurent Blvd, Suite 106, Ottawa, Ontario (Tel:
613-518-5886)
- 2 Pedorthists on Staff
- High Volume Clinical Practice with focus on Biomechanics and
Patient Gait
- Retail location offering Telemedicine, Orthotics, Compression
wear and Body Bracing products
MedX continues to focus on expanding its DermSecure® Screening
Platform network across North America. To date, its business model
has been focused on adding multiple market verticals, such as
Medical Clinic and Building Hubs, Medical Scanning Clinics, Mobile
and Remote Medical Practices, Esthetics and Skin Care Clinics.
The addition of ProMed Pharmacy to MedX's Pharmacy network will
allow for the "Walk-in-Patient" to get service for their
Dermatology concerns if they do not have a Family Doctor or do not
have time to get a direct referral.
"MedX remains focused on expanding its footprint into existing
and new target markets, and our team is continuing to establish and
accelerate many new commercial relationships and partnerships,"
stated Mike Druhan, MedX President, Dermatology Services. "I remain
confident in our team’s ability to expand MedX's teledermatology
platform to new markets and greatly improve outcomes for those
dermatology patients seeking high-quality, virtual services."
Teledermatology is a subspecialty of dermatology that offers
safe and effective virtual care – patient screening and assessment
– eliminating the need for in-person appointments with a
dermatologist. MedX is a global leader in teledermatology through
its high-definition image capture technology, SIAscopy®, and its
secure, cloud-based patient management system, DermSecure®, which
transmits and stores patient data throughout the assessment
process. MedX's SIAscopy® is the only technology globally that
captures five high-resolution images of suspicious moles, lesions
and skin conditions, including four spectrophotometric images 2mm
below the skin's surface. This technology provides detailed patient
scans for virtual dermatological assessment by a certified
dermatologist within 72 hours.
About MedX Health Corp.:
MedX, headquartered in Ontario, Canada, is a leading medical
device and software company focused on skin health with its
SIAscopy® on DermSecure® telemedicine platform, utilizing its
SIAscopy® technology. SIAscopy® is also imbedded in its products
SIAMETRICS®, SIMSYS®, and MoleMate®, which MedX manufactures in its
ISO 13485 certified facility. SIAMETRICS®, SIMSYS®, and MoleMate®
include hand-held devices that use patented technology utilizing
light and its remittance to view up to 2 mm beneath suspicious
moles and lesions in a pain free, non-invasive manner, with its
software then creating real-time images for physicians and
dermatologists to evaluate all types of moles or lesions within
seconds. These products are cleared by Health Canada, the U.S. Food
and Drug Administration, the Therapeutic Goods Administration and
Conformité Européenne for use in Canada, the US, Australia, New
Zealand, the European Union, Brazil and Turkey. Visit www.medxhealth.com.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
This Media Release may contain forward-looking statements,
which reflect the Company's current expectations regarding future
events. The forward-looking statements involve risks and
uncertainties.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220127005415/en/
Bill Mitoulas, Investor Relations MedX Health Corp.
bill@medxhealth.com +1-416-479-9547
Medx Health (TSXV:MDX)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Medx Health (TSXV:MDX)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024